# US 2019/0314309 A1 · Kit, composition, and combination therapy for fragile x syndrome

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0314309 A1
- Document ID: US20190314309A1
- Status: Published application
- Kind: A1
- Application number: 16/383,037
- Filed: 2019-04-12
- Published: 2019-10-17
- Earliest claimed: 2018-04-13
- Assignees: Healx Limited
- Applicants: Healx Limited
- Inventors: David Brown
- Web page: https://patentgrep.com/patent/US20190314309A1

## CPC

- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/05: Phenols {(cannabinoids A61K31/658)}
- A61K 31/135: having aromatic rings {, e.g. ketamine, nortriptyline (methadone A61K31/137)}
- A61K 31/35: having six-membered rings with one oxygen as the only ring hetero atom
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 31/353: 3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 31/65: Tetracyclines
- A61K 31/658: {o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol}
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Described herein are kits, compositions, and combination therapies comprising sulindac for use in the treatment of fragile X syndrome (FXS).

## Claims

### Claim at position 1

1-3. (canceled)

### Claim 4 (depends on 18)

The kit of claim 18, wherein Compound A is selected from the group consisting of ibudilast, sertraline, quercetin, cannabidiol, minocycline, topiramate and metoprolol.

### Claim at position 3

5-17. (canceled)

### Claim 18

A kit comprising:
(i) sulindac, or a pharmaceutically acceptable salt thereof; and
(ii) Compound A, or a pharmaceutically acceptable salt thereof, wherein Compound A is selected from the group consisting of:
minocycline, doxycycline, lovastatin, metformin, epigallocatechin gallate, lithium, tideglusib, lamotrigine, acamprosate, ganaxolone, basimglurant, mavoglurant, methylphenidate, L-carnitine, L-acetyl carnitine, zardaverine, ibudilast, metoprolol, penbutolol, fasudil, carbamazepine, midostaurin, sildenafil, tadalafil, gabapentin, stiripentol, ganaxolone, donepezil tetracyclines, cannabidiol, curcumin, simvastatin, atorvastatin, pravastatin, fluvastatin, rosuvastatin, pitavastatin, apigenin, telmisartan, medium and long chain fatty acids, indirubin, pregabalin, baclofen, arbaclofen, memantine, ethchlorvynol, fenobam, riluzole, crisaborole, S-rolipram, apremilast, cilomilast, roflumilast, dipyridamole, drotaverine, propentofylline, caffeine, papaverine, trapidil, flavoxate, amlexano X, pentoxifylline, propanolol, pindolol, acebutalol, bisoprolol, carvedilol, labetalol, metipranolol, oxprenalol, pindolol, tertatolol, timolol, topiramate, tianeptine, quercetin, disulfiram, imatinib, gefitinib, selumetinib, refametinib, fusidic acid, sertraline, lorazepam, phenobarbital, vardenafil, udenafil, avanafil, ruxolitinib, momelotinib, bortezomib, carfilzomib, carnosol, riluzole, luteolin, carnosic acid, resveratrol, methylphenidate, menadione, taurine, niacin, clorazepic acid, diazepam and other ‘azepam’ class drugs, chlordiazepoxide, staurosporin, gaboxadol, progabide, tulrampator, ketamine, decanoic acid, piracetam, pramiracetam, dexmethylphenidate, oglemilast, levetiracetam and vigabatrin.

### Claim at position 5

19-21. (canceled)

### Claim 22

A composition comprising:
(i) sulindac, or a pharmaceutically acceptable salt thereof; and
(ii) Compound A, or a pharmaceutically acceptable salt thereof, wherein Compound A is selected from the group consisting of:
minocycline, doxycycline, lovastatin, metformin, epigallocatechin gallate, lithium, tideglusib, lamotrigine, acamprosate, ganaxolone, basimglurant, mavoglurant, methylphenidate, L-carnitine, L-acetyl carnitine, zardaverine, ibudilast, metoprolol, penbutolol, fasudil, carbamazepine, midostaurin, sildenafil, tadalafil, gabapentin, stiripentol, donepezil, tetracyclines, cannabidiol, curcumin, simvastatin, atorvastatin, pravastatin, fluvastatin, rosuvastatin, pitavastatin, apigenin, telmisartan, medium and long chain fatty acids, indirubin, pregabalin, baclofen, arbaclofen, memantine, ethchlorvynol, fenobam, riluzole, crisaborole, S-rolipram, apremilast, cilomilast, roflumilast, dipyridamole, drotaverine, propentofylline, caffeine, papaverine, trapidil, flavoxate, amlexano X, pentoxifylline, propanolol, pindolol, acebutalol, bisoprolol, carvedilol, labetalol, metipranolol, oxprenalol, pindolol, tertatolol, timolol, topiramate, tianeptine, quercetin, disulfiram, imatinib, gefitinib, selumetinib, refametinib, fusidic acid, sertraline, lorazepam, phenobarbital, vardenafil, udenafil, avanafil, ruxolitinib, momelotinib, bortezomib, carfilzomib, carnosol, riluzole, luteolin, carnosic acid, resveratrol, methylphenidate, menadione, taurine, niacin, clorazepic acid, diazepam and other ‘azepam’ class drugs, chlordiazepoxide, staurosporin, gaboxadol, progabide, tulrampator, ketamine, decanoic acid, piracetam, pramiracetam, dexmethylphenidate, oglemilast, levetiracetam and vigabatrin.

### Claim 23

(canceled)

### Claim 24

A method of treating fragile x syndrome in a subject in need thereof comprising administering to the subject simultaneously, separately or sequentially:
(i) sulindac, or a pharmaceutically acceptable salt thereof; and
(ii) Compound A, or a pharmaceutically acceptable salt thereof, wherein Compound A is selected from the group consisting of:
minocycline, doxycycline, lovastatin, metformin, epigallocatechin gallate, lithium, tideglusib, lamotrigine, acamprosate, ganaxolone, basimglurant, mavoglurant, methylphenidate, L-carnitine, L-acetyl carnitine, zardaverine, ibudilast, metoprolol, penbutolol, fasudil, carbamazepine, midostaurin, sildenafil, tadalafil, gabapentin, stiripentol, ganaxolone, donepezil, tetracyclines, cannabidiol, curcumin, simvastatin, atorvastatin, pravastatin, fluvastatin, rosuvastatin, pitavastatin, apigenin, telmisartan, medium and long chain fatty acids, indirubin, pregabalin, baclofen, arbaclofen, memantine, ethchlorvynol, fenobam, riluzole, crisaborole, S-rolipram, apremilast, cilomilast, roflumilast, dipyridamole, drotaverine, propentofylline, caffeine, papaverine, trapidil, flavoxate, amlexano X, pentoxifylline, propanolol, pindolol, acebutalol, bisoprolol, carvedilol, labetalol, metipranolol, oxprenalol, pindolol, tertatolol, timolol, topiramate, tianeptine, quercetin, disulfiram, imatinib, gefitinib, selumetinib, refametinib, fusidic acid, sertraline, lorazepam, phenobarbital, vardenafil, udenafil, avanafil, ruxolitinib, momelotinib, bortezomib, carfilzomib, carnosol, riluzole, luteolin, carnosic acid, resveratrol, methylphenidate, menadione, taurine, niacin, clorazepic acid, diazepam and other ‘azepam’ class drugs, chlordiazepoxide, staurosporin, gaboxadol, progabide, tulrampator, ketamine, decanoic acid, piracetam, pramiracetam, dexmethylphenidate, oglemilast, levetiracetam and vigabatrin.

### Claim at position 9

25-29. (canceled)

### Claim 30 (depends on 24)

The method of claim 24, wherein Compound A is selected from the group consisting of minocycline, doxycycline, lovastatin, metformin, epigallocatechin gallate, quercetin, lithium, sertraline, topiramate, cannabidiol, tideglusib, lamotrigine, acamprosate, ganaxolone, basimglurant, mavoglurant, methylphenidate, L-carnitine, L-acetyl carnitine, zardaverine, ibudilast, metoprolol, penbutolol, fasudil, carbamazepine, midostaurin, gabapentin, stiripentol, fenobam and donepezil.

### Claim 31 (depends on 24)

The method of claim 24, wherein Compound A is selected from the group consisting of minocycline, doxycycline, lovastatin, metformin, lithium, sertraline, topiramate, cannabidiol, zardaverine, ibudilast, fasudil, midostaurin, fenobam, metoprolol and donepezil.

### Claim 32 (depends on 24)

The method of claim 24, wherein Compound A is selected from the group consisting of ibudilast, sertraline, quercetin, cannabidiol, minocycline, topiramate and metoprolol.

### Claim 33 (depends on 24)

The method of claim 24, wherein Compound A is selected from the group consisting of ibudilast, sertraline, quercetin, cannabidiol, minocycline and topiramate.

### Claim 34 (depends on 24)

The method of claim 24, wherein the subject exhibits signs of hyperactivity, social anxiety, memory loss, or disruptive behaviour.

### Claim 35 (depends on 24)

The method of claim 24, wherein the subject is human.

### Claim 36 (depends on 24)

The method of claim 24, wherein sulindac and Compound A are administered simultaneously in a single dose once per day.

### Claim 37 (depends on 36)

The method of claim 36, wherein the single dose comprises 200 mg to 400 mg of sulindac.

### Claim 38 (depends on 24)

The method of claim 24, wherein sulindac and Compound A are administered simultaneously in a single dose twice per day.

### Claim 39 (depends on 38)

The method of claim 38, wherein the single dose comprises 150 mg to 200 mg of sulindac.

### Claim 40 (depends on 24)

The method of claim 24, wherein sulindac and Compound A are administered orally.

### Claim 41 (depends on 24)

The method of claim 24, wherein sulindac and Compound A are administered parenterally, transdermally, sublingually, rectally or by inhalation.

### Claim 42 (depends on 24)

The method of claim 24, wherein the subject is human; and sulindac and Compound A are administered simultaneously in a single dose once per day.

### Claim 43 (depends on 24)

The method of claim 24, wherein the subject is human; and sulindac and Compound A are administered simultaneously in a single dose twice per day.

### Claim 44 (depends on 24)

The method of claim 24, wherein Compound A is selected from the group consisting of ibudilast, sertraline, quercetin, cannabidiol, minocycline and topiramate; the subject is human; and sulindac and Compound A are administered simultaneously in a single dose once per day.

### Claim 45 (depends on 24)

The method of claim 24, wherein Compound A is selected from the group consisting of ibudilast, sertraline, quercetin, cannabidiol, minocycline and topiramate; the subject is human; and sulindac and Compound A are administered simultaneously in a single dose twice per day.
